Phase 1
Completed N=46
The Women's Recovery Group Study: Stage I Trial
Alcohol-Related Disorders · Substance-Related Disorders
Source: ClinicalTrials.gov NCT00230100 ↗
Enrolled (actual)
46
Serious AEs
0.0%
Results posted
Feb 2017
Primary outcomePrimary: Change in Mean Days of Any Substance Use for Women — -3.93; -1.74; -4.45; 0.60 Days of any substance use per month — p=<0.05
Summary
The purpose of this study was to develop a gender-specific 12-session, manual-based relapse prevention group for women with substance use disorders (SUDs).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Mean Days of Any Substance Use for Women |
-3.93; -1.74; -4.45; 0.60 | <0.05 sig |
| PRIMARY Change in Mean Number of Drinking Days for Women |
-1.95; -0.23; -2.40; 1.72 | <0.05 sig |
| SECONDARY Change in Mean Number of Drinks Per Drinking Day for Women |
-0.62; 0.36; -1.19; 1.66 | <0.05 sig |
| SECONDARY Change in Mean Addiction Severity Index Alcohol Composite Score for Women |
-0.14; -0.14; -0.23; -0.03 | <0.05 sig |
Eligibility Criteria
Inclusion criteria
Participants were included in the study if they:
- were diagnosed with at least one substance dependence other than nicotine dependence based on the Structured Clinical Interview for DSM-IV at the time of enrollment
- used substances within 60 days of baseline assessment
- were 18 years of age or older
- expressed intention to remain within the geographic area to return for follow-up assessments
- signed permission for the research team to communicate with any other mental health professional from whom they were receiving care
Patients were excluded if they:
- had certain co-occurring diagnoses (i.e., bipolar, post-traumatic stress, or psychotic disorders) at the time of enrollment
- were mandated to treatment
- were in residential treatment restricting substance use during the group treatment phase
- participated in concurrent substance abuse treatment group (not including self-help) during the 12-week group treatment phase
- showed clinical indication for medical detoxification (these patients were eligible to enter the study after detoxification)
Data sourced from ClinicalTrials.gov (NCT00230100). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.